MeSH tree: C23.550.727.700
Today, treatment decisions for patients with mantle cell lymphoma are heavily based on age alone, although the disease can range from slow-growing (indolent) to very aggressive. In a new journal article, Ingrid Glimelius ...
Sep 4, 2026
0
5
Researchers identified a six-gene signature in microscopic colorectal cancer (CRC) liver metastases that may help predict recurrence after treatment. The findings suggest these tiny, often undetectable tumor deposits could ...
Jul 9, 2026
0
4
Researchers at The University of Texas MD Anderson Cancer Center were able to eradicate measurable residual disease (MRD) in B-cell acute lymphoblastic leukemia (ALL) patients, a critical step in improving long-term survival ...
Jul 7, 2026
0
7
Bladder cancer arises from the lining of the bladder, the organ that stores urine, and is one of the most common cancers in the United States. Most patients are diagnosed at an early stage called non-muscle invasive bladder ...
Apr 8, 2026
0
10
Cancer researchers are making strides in efforts to use genetic profiling to develop a more precise understanding of the response to treatment of acute myeloid leukemia (AML), a rare but aggressive blood cancer.
Feb 19, 2026
0
13
Low-grade brain tumors known as IDH-mutant gliomas CNS WHO grade 2 are life-threatening in spite of their slow growth. Neurosurgeons across the globe are faced with the question as to striking the correct balance between ...
Jan 19, 2026
0
23
Patients with relapsed or refractory (R/R) multiple myeloma who received a combination of teclistamab, a bispecific monoclonal antibody, and daratumumab, a CD38-directed monoclonal antibody, were 83% more likely to be alive ...
Dec 9, 2025
0
17
Researchers from The University of Texas MD Anderson Cancer Center presented promising new data from two ongoing studies of pivekimab sunirine (PVEK), an antibody-drug conjugate targeting CD123, in treating two aggressive ...
Dec 9, 2025
0
13
According to a new trial, patients with chronic lymphocytic leukemia (CLL) show comparable outcomes whether they receive a single-agent treatment indefinitely or a combination treatment for a fixed period of time.
Dec 8, 2025
0
14
A chemotherapy-free combination treatment outperformed a combination of targeted therapy and chemotherapy among patients with Ph+ acute lymphoblastic leukemia (ALL) in a new study. The Phase III trial, which included adult ...
Dec 8, 2025
0
13
